Reach Us +44-1904-929220
Loss of ANXA7 Expression is Associated with Poor Patient Survival in Ovarian Cancer | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Loss of ANXA7 Expression is Associated with Poor Patient Survival in Ovarian Cancer

Meera Srivastava1*, Ofer Eidelman1, Lukas Bubendorf2, Guido Sauter3, Holger Moch4 and Harvey B. Pollard1

1Department of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University School of Medicine (USUHS), Bethesda, MD. 20814

2Institute for Pathology, University of Basel, Switzerland

3Department of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany

4Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland

*Corresponding Author:
Meera Srivastava, Ph.D
Department of Anatomy and Cell Biology
USU School of Medicine, 4301 Jones Bridge Road
Bethesda, MD 20814
Tel: 301-295-3204
Fax: 301-295-1786
Email: [email protected]

Received Date: July 19 Accepted Date: August 22, 2011; Published Date: August 26, 2011

Citation: Srivastava M, Eidelman O, Bubendorf L, Sauter G, Pollard HB, et al. (2011) Loss of ANXA7 Expression is Associated with Poor Patient Survival in Ovarian Cancer. J Mol Biomark Diagn 2:113. doi:10.4172/2155-9929.1000113

Copyright: © 2011 Srivastava M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited


Epithelial ovarian cancer is morphologically heterogeneous being classified as serous, endometrioid, clear cell, or mucinous. Molecular genetic analysis has suggested a role for tumor suppressor genes located at chromosome 10q in epithelial ovarian cancer pathogenesis. Our objective is to evaluate the expression of ANXA7, a novel tumor suppressor gene located on 10q21, in these epithelial ovarian cancer subtypes, and to investigate its correlation with patient survival. ANXA7 is ubiquitously expressed in small amounts in nearly every normal cell and the Anxa7 (+/-) knockout mouse has a cancer prone phenotype. Altered ANXA7 protein levels are associated with prognostically challenging aggressive forms of prostate and breast cancer. So far, information is not available regarding the association of ANXA7 expression in ovarian cancer and patient survival. Therefore, we used human tumor tissue microarray (TMA) technology in order to evaluate the ANXA7 immunoreactivity as possible diagnostic and/or prognostic marker of ovarian cancer by immunoperoxidase assay using ANXA7 monoclonal antibody. Using a 129 case diagnostic human tumor tissue microarray, we report that the expression of ANXA7 is significantly reduced and is associated with disease progression. Furthermore, using a separate 301 case retrospective prognostic tumor tissue microarray, we find that loss of ANXA7 expression is also significantly associated with poor over-all patient survival. We conclude that ANXA7 may be a new prognostic marker or a target for improving the treatment efficiency of patients with ovarian cancers.


Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page